The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor–targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen–based therapy have become available for men with metastatic PCa. Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

中文翻译：

---

EAU-EANM-ESTRO-ESUR-ISUP-SIOG 前列腺癌指南。第二部分 — 2024 年更新：复发性和转移性前列腺癌的治疗


欧洲泌尿外科协会 (EAU) - 欧洲核医学协会 (EANM) - 欧洲放射治疗和肿瘤学会 (ESTRO) - 欧洲泌尿生殖放射学会 (ESUR) - 国际泌尿病理学会 (ISUP) - 国际老年病学会关于复发性、转移性和去势抵抗性前列腺癌 (PCa) 治疗的肿瘤学 (SIOG) 指南已更新。我们在此提供 2024 年指南的摘要。该小组对涵盖 2020 年至 2023 年时间范围的新数据进行了文献综述。在对证据进行系统审查的基础上，更新了指南并添加了每项建议的强度评级。主要治疗后复发 PCa 的风险分层可以指导挽救治疗决策。新的治疗选择，如雄激素受体靶向药物 (ARTA)、ARTA + 化疗组合、PARP 抑制剂及其组合，以及基于前列腺特异性膜抗原的治疗，已可供患有转移性 PCa 的男性使用。复发性、转移性和去势抵抗性前列腺癌的证据正在迅速发展。这些指南反映了 PCa 管理的多学科性质。完整版本可在线获取 (http://uroweb.org/guideline/prostate-cancer/)。本文总结了 2024 年复发性、转移性和去势抵抗性前列腺癌治疗指南。这些指南以证据为基础，指导医生与患者讨论治疗决策。该指南每年都会更新。